ID

18029

Description

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00141700

Link

https://clinicaltrials.gov/show/NCT00141700

Keywords

Versions (1)
  1. 10/15/16 10/15/16 -
Uploaded on

October 15, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Lymphoma, Non-Hodgkin's NCT00141700

English

Eligibility Lymphoma, Non-Hodgkin's NCT00141700

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically documented, aggressive and/or intermediate grade and high-grade b cell nhl, cd20 positive.
Description

Aggressive Non-Hodgkin Lymphoma CD20 antigen positive | Intermediate Grade B-Cell Non-Hodgkin's Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma

Data type

boolean

Alias
UMLS CUI [1,1]
C1332225
UMLS CUI [1,2]
C3888518
UMLS CUI [2]
C1512858
UMLS CUI [3]
C1512431
histologic subtypes include follicular large cell, diffuse small cleaved cell, diffuse mixed small and large cell, diffuse large cell, anaplastic large cell, and mantle cell lymphomas.
Description

Lymphoma, Large-Cell, Follicular | lymphoma; cleaved cell, small cell (diffuse) | Diffuse Mixed-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Anaplastic large B-cell lymphoma | Mantle cell lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C0079745
UMLS CUI [2]
C1398349
UMLS CUI [3]
C0079757
UMLS CUI [4]
C0079744
UMLS CUI [5]
C1321546
UMLS CUI [6]
C0334634
nhl must have high-intermediate or high international prognostic index (standard ipi) score at diagnosis. mantle cell nhl is eligible regardless of ipi score.
Description

Lymphoma, Non-Hodgkin | Lymphoma, Intermediate-Grade | High Grade Lymphoma | International Prognostic Index | Mantle cell lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C0024305
UMLS CUI [2]
C0079741
UMLS CUI [3]
C0079740
UMLS CUI [4]
C1512894
UMLS CUI [5]
C0334634
complete or partial response to first-line therapy.
Description

First line treatment In complete remission | First line treatment partial response

Data type

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C0677874
UMLS CUI [2,1]
C1708063
UMLS CUI [2,2]
C1521726
treated cns or meningeal disease, using radiation therapy and/or intrathecal chemotherapy, is allowed. patients with meningeal disease must have cytologically negative csf at time of study entry.
Description

CNS disorder Treated | Meningeal disorder Treated | Therapeutic radiology procedure | intrathecal chemotherapy | Cerebrospinal Fluid Negative

Data type

boolean

Alias
UMLS CUI [1,1]
C0007682
UMLS CUI [1,2]
C1522326
UMLS CUI [2,1]
C0154728
UMLS CUI [2,2]
C1522326
UMLS CUI [3]
C1522449
UMLS CUI [4]
C1517560
UMLS CUI [5,1]
C0007806
UMLS CUI [5,2]
C1513916
cumulative total doxorubicin: <500 mg/m2
Description

Doxorubicin Cumulative Dose

Data type

boolean

Alias
UMLS CUI [1,1]
C0013089
UMLS CUI [1,2]
C2986497
performance score 0-2
Description

performance status

Data type

boolean

Alias
UMLS CUI [1]
C1518965
patients with a prior malignancy are eligible if they were treated with curative intent and have no evidence of active disease.
Description

curative treatment Malignant Neoplasms | Disease Evidence

Data type

boolean

Alias
UMLS CUI [1,1]
C1273390
UMLS CUI [1,2]
C0006826
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C3887511
patients must not be pregnant or nursing.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant or nursing
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Back to the top of the page

Similar models

Eligibility Lymphoma, Non-Hodgkin's NCT00141700

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Aggressive Non-Hodgkin Lymphoma CD20 antigen positive | Intermediate Grade B-Cell Non-Hodgkin's Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma
Item
histologically documented, aggressive and/or intermediate grade and high-grade b cell nhl, cd20 positive.
boolean
C1332225 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
C1512858 (UMLS CUI [2])
C1512431 (UMLS CUI [3])
Lymphoma, Large-Cell, Follicular | lymphoma; cleaved cell, small cell (diffuse) | Diffuse Mixed-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Anaplastic large B-cell lymphoma | Mantle cell lymphoma
Item
histologic subtypes include follicular large cell, diffuse small cleaved cell, diffuse mixed small and large cell, diffuse large cell, anaplastic large cell, and mantle cell lymphomas.
boolean
C0079745 (UMLS CUI [1])
C1398349 (UMLS CUI [2])
C0079757 (UMLS CUI [3])
C0079744 (UMLS CUI [4])
C1321546 (UMLS CUI [5])
C0334634 (UMLS CUI [6])
Lymphoma, Non-Hodgkin | Lymphoma, Intermediate-Grade | High Grade Lymphoma | International Prognostic Index | Mantle cell lymphoma
Item
nhl must have high-intermediate or high international prognostic index (standard ipi) score at diagnosis. mantle cell nhl is eligible regardless of ipi score.
boolean
C0024305 (UMLS CUI [1])
C0079741 (UMLS CUI [2])
C0079740 (UMLS CUI [3])
C1512894 (UMLS CUI [4])
C0334634 (UMLS CUI [5])
First line treatment In complete remission | First line treatment partial response
Item
complete or partial response to first-line therapy.
boolean
C1708063 (UMLS CUI [1,1])
C0677874 (UMLS CUI [1,2])
C1708063 (UMLS CUI [2,1])
C1521726 (UMLS CUI [2,2])
CNS disorder Treated | Meningeal disorder Treated | Therapeutic radiology procedure | intrathecal chemotherapy | Cerebrospinal Fluid Negative
Item
treated cns or meningeal disease, using radiation therapy and/or intrathecal chemotherapy, is allowed. patients with meningeal disease must have cytologically negative csf at time of study entry.
boolean
C0007682 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C0154728 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C1522449 (UMLS CUI [3])
C1517560 (UMLS CUI [4])
C0007806 (UMLS CUI [5,1])
C1513916 (UMLS CUI [5,2])
Doxorubicin Cumulative Dose
Item
cumulative total doxorubicin: <500 mg/m2
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
performance status
Item
performance score 0-2
boolean
C1518965 (UMLS CUI [1])
curative treatment Malignant Neoplasms | Disease Evidence
Item
patients with a prior malignancy are eligible if they were treated with curative intent and have no evidence of active disease.
boolean
C1273390 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C3887511 (UMLS CUI [2,2])
Pregnancy | Breast Feeding
Item
patients must not be pregnant or nursing.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Informed Consent
Item
informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial